Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma

Conditions

• Disease-free Survival Rate

Eligibility Criteria

Sex

ALL

Age

N/A - 70 Years

Healthy Volunteers

Not accepted

Interventions

• Camrelizumab+Chemotherapy+Chemoradiotherapy — DRUG
  Patients received neoadjuvant Camrelizumab 200mg combined with chemotherapy (Cisplatin 20mg/m2, Day 1-3, Docetaxel 75mg/m2, Day 1) for 2 cycles every 21 days, followed by concurrent chemoradiotherapy with Camrelizumab monotherapy maintenance

Study Details

To see the effect if a combination of neoadjuvant chemotherapy combined with Camrelizumab followed by chemoradiotherapy in treating patients without distant metastasis nasopharyngeal carcinoma

Key Dates

Start date

Mar 20, 2021

Status verified

Mar 2021

Primary completion

Mar 20, 2023

Completion

Mar 20, 2025

Study Design

Enrollment

59 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Camrelizumab+Chemotherapy+Chemoradiotherapy
  Patients received neoadjuvant Camrelizumab 200mg combined with chemotherapy (Cisplatin 20mg/m2, Day 1-3, Docetaxel 75mg/m2, Day 1) for 2 cycles every 21 days, followed by concurrent chemoradiotherapy with Camrelizumab monotherapy maintenance

Primary Outcome Measure

Disease-free survival（DFS）rate of 3 years [ Time Frame: 3 years ]